@article{f8607c70cdf8430698b856606f79cff0,
title = "The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation",
keywords = "BOLD-100, KP1339, ruthenium, chemotherapy resistance, 2-deoxy-d-glucose, glycolysis, ER stress, autophagy, lysosome, colon cancer, pancreatic cancer, CELL LUNG-CANCER, ENERGY-METABOLISM, PROSTATE-CANCER, 2-DEOXY-D-GLUCOSE, EXPRESSION, 2-DEOXYGLUCOSE, AUTOPHAGY, DRUG, SUPPRESSES, RESISTANCE, Lysosome, Autophagy, Colon cancer, 2-deoxy-D-glucose, Chemotherapy resistance, Ruthenium, BOLD-100/KP1339, Pancreatic cancer, Glycolysis",
author = "Dina Baier and Beatrix Sch{\"o}nhacker-Alte and Mate Rusz and Christine Pirker and Thomas Mohr and Theresa Mendrina and Dominik Kirchhofer and Meier-Menches, {Samuel M.} and Katharina Hohenwallner and Martin Schaier and Evelyn Rampler and Gunda Koellensperger and Petra Heffeter and Bernhard Keppler and Walter Berger",
note = "Accession Number: WOS:000764715400001 PubMed ID: 35213972",
year = "2022",
month = jan,
day = "20",
doi = "10.3390/pharmaceutics14020238",
language = "English",
volume = "14",
journal = "Pharmaceutics",
publisher = "MDPI AG",
number = "2",
}
